Consilium Strategic Communications is handling the merger of Oculis and European Biotech Acquisition Corp. in a SPAC deal valued in the $220M range. The combined entity will trade on the NASDAQ.
Switzerland-based Oculis is a biopharma company focused on developing treatments to save sight and improve eye care.
Riad Sherif, Oculis CEO, said proceeds from the EBAC transaction will be used to accelerate development of drugs in its pipeline.
EBAC has screened over 100 European biotech companies.
CEO Eduardo Bravo called Oculis a prime example of what his company wants to invest in.
He said Oculis has “great innovation, a well thought-out strategy and an experienced management team to bring promising therapies to market for patients suffering from eye disease.”
Oculis has product candidates to treat macular edema, dry eye disease and nero-retina indicators such as glaucoma.
Consilium Strategic Communications, which works in the healthcare PR and IR space, has Amber Fennell, Matthew Cole and David Daley working the Oculis deal.